Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 756 entries
Sorted by: Best Match Show Resources per page
Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2).

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion

Atalay F, Ateşoğlu EB.
PMID: 26855506
Indian J Hematol Blood Transfus. 2016 Mar;32(1):46-53. doi: 10.1007/s12288-015-0509-2. Epub 2015 Feb 01.

Only one-third of elderly (>60 years) AML and MDS-RAEB2 patients may receive intensive chemotherapy treatment alternatives that are limited in this patient group due to the potential of severe toxicity. Previous studies have shown that azacitidine and low dose...

Cite
Atalay F, Ateşoğlu EB. Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2). Indian J Hematol Blood Transfus. 2015;32(1):46-53doi: 10.1007/s12288-015-0509-2.
Atalay, F., & Ateşoğlu, E. B. (2016). Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2). Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 32(1), 46-53. https://doi.org/10.1007/s12288-015-0509-2
Atalay, Figen, and Ateşoğlu, Elif Birtaş. "Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2)." Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion vol. 32,1 (2016): 46-53. doi: https://doi.org/10.1007/s12288-015-0509-2
Atalay F, Ateşoğlu EB. Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2). Indian J Hematol Blood Transfus. 2016 Mar;32(1):46-53. doi: 10.1007/s12288-015-0509-2. Epub 2015 Feb 01. PMID: 26855506; PMCID: PMC4733667.
Copy Download .nbib Format: NLM
Targeting SLUG sensitizes leukemia cells to ADR-induced apoptosis.

International journal of clinical and experimental medicine

Wei CR, Liu J, Yu XJ.
PMID: 26885188
Int J Clin Exp Med. 2015 Dec 15;8(12):22139-48. eCollection 2015.

BACKGROUND AND AIMS: Slug is an E-cadherin repressor and a suppressor of PUMA (p53 upregulated modulator of apoptosis) and it has recently been demonstrated that Slug plays an important role in controlling apoptosis. In this study, we examined whether...

Cite
Wei CR, Liu J, Yu XJ. Targeting SLUG sensitizes leukemia cells to ADR-induced apoptosis. Int J Clin Exp Med. 2015;8(12):22139-48
Wei, C. R., Liu, J., & Yu, X. J. (2015). Targeting SLUG sensitizes leukemia cells to ADR-induced apoptosis. International journal of clinical and experimental medicine, 8(12), 22139-48.
Wei, Chang-Rong, et al. "Targeting SLUG sensitizes leukemia cells to ADR-induced apoptosis." International journal of clinical and experimental medicine vol. 8,12 (2015): 22139-48.
Wei CR, Liu J, Yu XJ. Targeting SLUG sensitizes leukemia cells to ADR-induced apoptosis. Int J Clin Exp Med. 2015 Dec 15;8(12):22139-48. eCollection 2015. PMID: 26885188; PMCID: PMC4729974.
Copy Download .nbib Format: NLM
The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents.

Molecular & cellular oncology

Yu Y, Xie Y, Cao L, Yang L, Yang M, Lotze MT, Zeh HJ, Kang R, Tang D.
PMID: 27308510
Mol Cell Oncol. 2015 May 26;2(4):e1054549. doi: 10.1080/23723556.2015.1054549. eCollection 2015.

Acute myeloid leukemia (AML) is the most common type of leukemia in adults. Development of resistance to chemotherapeutic agents is a major hurdle in the effective treatment of patients with AML. The quinazolinone derivative erastin was originally identified in...

Cite
Yu Y, Xie Y, Cao L, et al. The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol Cell Oncol. 2015;2(4):e1054549doi: 10.1080/23723556.2015.1054549.
Yu, Y., Xie, Y., Cao, L., Yang, L., Yang, M., Lotze, M. T., Zeh, H. J., Kang, R., & Tang, D. (2015). The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Molecular & cellular oncology, 2(4), e1054549. https://doi.org/10.1080/23723556.2015.1054549
Yu, Yan, et al. "The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents." Molecular & cellular oncology vol. 2,4 (2015): e1054549. doi: https://doi.org/10.1080/23723556.2015.1054549
Yu Y, Xie Y, Cao L, Yang L, Yang M, Lotze MT, Zeh HJ, Kang R, Tang D. The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol Cell Oncol. 2015 May 26;2(4):e1054549. doi: 10.1080/23723556.2015.1054549. eCollection 2015. PMID: 27308510; PMCID: PMC4905356.
Copy Download .nbib Format: NLM
Shoulder Myeloid Sarcoma: An Initial Presentation of CML Blast Crisis.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion

Jain A, Sahu KK, Sharma S, Rajwanshi A, Suri V, Malhotra P.
PMID: 27408438
Indian J Hematol Blood Transfus. 2016 Jun;32:361-3. doi: 10.1007/s12288-016-0656-0. Epub 2016 Feb 09.

Myeloid sarcoma (MS) represents extra medullary accumulation of the immature cells of granulocytic series and occurs most commonly in the setting of acute myelogenous leukemia. Its occurrence in chronic myeloid leukemia (CML), myelodysplastic syndrome and other myeloproliferative neoplasm is...

Cite
Jain A, Sahu KK, Sharma S, et al. Shoulder Myeloid Sarcoma: An Initial Presentation of CML Blast Crisis. Indian J Hematol Blood Transfus. 2016;32:361-3doi: 10.1007/s12288-016-0656-0.
Jain, A., Sahu, K. K., Sharma, S., Rajwanshi, A., Suri, V., & Malhotra, P. (2016). Shoulder Myeloid Sarcoma: An Initial Presentation of CML Blast Crisis. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 32361-3. https://doi.org/10.1007/s12288-016-0656-0
Jain, Ankur, et al. "Shoulder Myeloid Sarcoma: An Initial Presentation of CML Blast Crisis." Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion vol. 32 (2016): 361-3. doi: https://doi.org/10.1007/s12288-016-0656-0
Jain A, Sahu KK, Sharma S, Rajwanshi A, Suri V, Malhotra P. Shoulder Myeloid Sarcoma: An Initial Presentation of CML Blast Crisis. Indian J Hematol Blood Transfus. 2016 Jun;32:361-3. doi: 10.1007/s12288-016-0656-0. Epub 2016 Feb 09. PMID: 27408438; PMCID: PMC4925556.
Copy Download .nbib Format: NLM
Granulocyte colony-stimulating factor inhibits CXCR4/SDF-1α signaling and overcomes stromal-mediated drug resistance in the HL-60 cell line.

Experimental and therapeutic medicine

Sheng X, Zhong H, Wan H, Zhong J, Chen F.
PMID: 27347068
Exp Ther Med. 2016 Jul;12(1):396-404. doi: 10.3892/etm.2016.3268. Epub 2016 Apr 20.

Combining cytarabine, aclarubicin and granulocyte colony-stimulating factor (G-CSF) has demonstrated marked efficacy in the treatment of elderly and relapsed/refractory patients with acute myeloid leukemia (AML); however, the role of G-CSF remains poorly understood. The present study aimed to investigate...

Cite
Sheng X, Zhong H, Wan H, et al. Granulocyte colony-stimulating factor inhibits CXCR4/SDF-1α signaling and overcomes stromal-mediated drug resistance in the HL-60 cell line. Exp Ther Med. 2016;12(1):396-404doi: 10.3892/etm.2016.3268.
Sheng, X., Zhong, H., Wan, H., Zhong, J., & Chen, F. (2016). Granulocyte colony-stimulating factor inhibits CXCR4/SDF-1α signaling and overcomes stromal-mediated drug resistance in the HL-60 cell line. Experimental and therapeutic medicine, 12(1), 396-404. https://doi.org/10.3892/etm.2016.3268
Sheng, Xianfu, et al. "Granulocyte colony-stimulating factor inhibits CXCR4/SDF-1α signaling and overcomes stromal-mediated drug resistance in the HL-60 cell line." Experimental and therapeutic medicine vol. 12,1 (2016): 396-404. doi: https://doi.org/10.3892/etm.2016.3268
Sheng X, Zhong H, Wan H, Zhong J, Chen F. Granulocyte colony-stimulating factor inhibits CXCR4/SDF-1α signaling and overcomes stromal-mediated drug resistance in the HL-60 cell line. Exp Ther Med. 2016 Jul;12(1):396-404. doi: 10.3892/etm.2016.3268. Epub 2016 Apr 20. PMID: 27347068; PMCID: PMC4906714.
Copy Download .nbib Format: NLM
Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience.

South Asian journal of cancer

Bashir Y, Geelani S, Bashir N, Mir SA, Mushtaq M, Jan MA, Rasool J.
PMID: 25839010
South Asian J Cancer. 2015 Jan-Mar;4(1):4-6. doi: 10.4103/2278-330X.149918.

PURPOSE: To highlight the acceptable results seen after use of low dose cytarabine in elderly patients of acute myeloid leukemia (AML) with comorbidities.MATERIALS AND METHODS: This was a prospective study carried on 30 newly diagnosed patients of AML over...

Cite
Bashir Y, Geelani S, Bashir N, et al. Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience. South Asian J Cancer. 2015;4(1):4-6doi: 10.4103/2278-330X.149918.
Bashir, Y., Geelani, S., Bashir, N., Mir, S. A., Mushtaq, M., Jan, M. A., & Rasool, J. (2015). Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience. South Asian journal of cancer, 4(1), 4-6. https://doi.org/10.4103/2278-330X.149918
Bashir, Yasir, et al. "Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience." South Asian journal of cancer vol. 4,1 (2015): 4-6. doi: https://doi.org/10.4103/2278-330X.149918
Bashir Y, Geelani S, Bashir N, Mir SA, Mushtaq M, Jan MA, Rasool J. Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience. South Asian J Cancer. 2015 Jan-Mar;4(1):4-6. doi: 10.4103/2278-330X.149918. PMID: 25839010; PMCID: PMC4382784.
Copy Download .nbib Format: NLM
Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation.

Stem cells and cloning : advances and applications

Shanbhag S, Smith MR, Emmons RV.
PMID: 24198514
Stem Cells Cloning. 2010 Jul 07;3:93-102. doi: 10.2147/sccaa.s7016.

Mantle cell lymphoma (MCL) is a type of non-Hodgkins lymphoma (NHL) associated with poor progression-free and overall survival. There is a high relapse rate with conventional cytotoxic chemotherapy. Intensive combination chemotherapy including rituximab, dose intense CHOP- (cyclophosphamide-doxorubicin-vincristine-prednisone) like regimens,...

Cite
Shanbhag S, Smith MR, Emmons RV. Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation. Stem Cells Cloning. 2010;3:93-102doi: 10.2147/sccaa.s7016.
Shanbhag, S., Smith, M. R., & Emmons, R. V. (2010). Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation. Stem cells and cloning : advances and applications, 393-102. https://doi.org/10.2147/sccaa.s7016
Shanbhag, Satish, et al. "Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation." Stem cells and cloning : advances and applications vol. 3 (2010): 93-102. doi: https://doi.org/10.2147/sccaa.s7016
Shanbhag S, Smith MR, Emmons RV. Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation. Stem Cells Cloning. 2010 Jul 07;3:93-102. doi: 10.2147/sccaa.s7016. PMID: 24198514; PMCID: PMC3781733.
Copy Download .nbib Format: NLM
Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report.

Oncology letters

Deng Q, Li JY, Liu PJ, Zhao MF.
PMID: 25663885
Oncol Lett. 2015 Mar;9(3):1217-1220. doi: 10.3892/ol.2015.2870. Epub 2015 Jan 13.

Despite advances in the treatment of acute myeloid leukemia (AML) in recent years, the outcome of elderly AML patients with antecedent hematological disorders remains unsatisfactory. The present study describes a case of complete remission in an elderly patient with...

Cite
Deng Q, Li JY, Liu PJ, et al. Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report. Oncol Lett. 2015;9(3):1217-1220doi: 10.3892/ol.2015.2870.
Deng, Q., Li, J. Y., Liu, P. J., & Zhao, M. F. (2015). Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report. Oncology letters, 9(3), 1217-1220. https://doi.org/10.3892/ol.2015.2870
Deng, Qi, et al. "Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report." Oncology letters vol. 9,3 (2015): 1217-1220. doi: https://doi.org/10.3892/ol.2015.2870
Deng Q, Li JY, Liu PJ, Zhao MF. Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report. Oncol Lett. 2015 Mar;9(3):1217-1220. doi: 10.3892/ol.2015.2870. Epub 2015 Jan 13. PMID: 25663885; PMCID: PMC4315126.
Copy Download .nbib Format: NLM
Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 cases.

Molecular and clinical oncology

Liu J, Sun XF, Qian J, Bai XY, Zhu H, Cui QU, Li XY, Chen YD, Wang YM, Liu YB.
PMID: 26171213
Mol Clin Oncol. 2015 Jul;3(4):949-953. doi: 10.3892/mco.2015.566. Epub 2015 May 12.

The incidence of primary central nervous system lymphoma (PCNSL) has increased in the last two decades and the clinical research regarding the treatment for PCNSL patients has also increased. However, the optimal induction chemotherapy has not been fully established....

Cite
Liu J, Sun XF, Qian J, et al. Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 cases. Mol Clin Oncol. 2015;3(4):949-953doi: 10.3892/mco.2015.566.
Liu, J., Sun, X. F., Qian, J., Bai, X. Y., Zhu, H., Cui, Q. U., Li, X. Y., Chen, Y. D., Wang, Y. M., & Liu, Y. B. (2015). Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 cases. Molecular and clinical oncology, 3(4), 949-953. https://doi.org/10.3892/mco.2015.566
Liu, Jing, et al. "Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 cases." Molecular and clinical oncology vol. 3,4 (2015): 949-953. doi: https://doi.org/10.3892/mco.2015.566
Liu J, Sun XF, Qian J, Bai XY, Zhu H, Cui QU, Li XY, Chen YD, Wang YM, Liu YB. Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 cases. Mol Clin Oncol. 2015 Jul;3(4):949-953. doi: 10.3892/mco.2015.566. Epub 2015 May 12. PMID: 26171213; PMCID: PMC4486824.
Copy Download .nbib Format: NLM
[Short Course High Dose Mitoxantrone with Cytarabine for Treatment of Refractory and Relapsed Acute Leukemia].

Zhongguo shi yan xue ye xue za zhi

Wang HX, Xue M, Zhu L, Yan HM, Ji SQ.
PMID: 12578650
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2001 Mar;9(1):70-72.

Although chemotherapy can achieve a high rate of disease remission in patients with newly diagnosed acute leukemia, patients with recurrent or refractory leukemia generally have a poorer rate of response. This study was designed to assess the utility of...

Cite
Wang HX, Xue M, Zhu L, et al. [Short Course High Dose Mitoxantrone with Cytarabine for Treatment of Refractory and Relapsed Acute Leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2001;9(1):70-72
Wang, H. X., Xue, M., Zhu, L., Yan, H. M., & Ji, S. Q. (2001). [Short Course High Dose Mitoxantrone with Cytarabine for Treatment of Refractory and Relapsed Acute Leukemia]. Zhongguo shi yan xue ye xue za zhi, 9(1), 70-72.
Wang, Heng-Xiang, et al. "[Short Course High Dose Mitoxantrone with Cytarabine for Treatment of Refractory and Relapsed Acute Leukemia]." Zhongguo shi yan xue ye xue za zhi vol. 9,1 (2001): 70-72.
Wang HX, Xue M, Zhu L, Yan HM, Ji SQ. [Short Course High Dose Mitoxantrone with Cytarabine for Treatment of Refractory and Relapsed Acute Leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2001 Mar;9(1):70-72. Chinese. PMID: 12578650.
Copy Download .nbib Format: NLM
Novel Marine Compounds: Anticancer or Genotoxic?.

Journal of biomedicine & biotechnology

Arif JM, Al-Hazzani AA, Kunhi M, Al-Khodairy F.
PMID: 15240919
J Biomed Biotechnol. 2004;2004(2):93-98. doi: 10.1155/S1110724304307060.

In the past several decades, marine organisms have generously gifted to the pharmaceutical industries numerous naturally bioactive compounds with antiviral, antibacterial, antimalarial, anti-inflammatory, antioxidant, and anticancer potentials. But till date only few anticancer drugs (cytarabine, vidarabine) have been commercially...

Cite
Arif JM, Al-Hazzani AA, Kunhi M, et al. Novel Marine Compounds: Anticancer or Genotoxic?. J Biomed Biotechnol. 2004;2004(2):93-98doi: 10.1155/S1110724304307060.
Arif, J. M., Al-Hazzani, A. A., Kunhi, M., & Al-Khodairy, F. (2004). Novel Marine Compounds: Anticancer or Genotoxic?. Journal of biomedicine & biotechnology, 2004(2), 93-98. https://doi.org/10.1155/S1110724304307060
Arif, Jamal M., et al. "Novel Marine Compounds: Anticancer or Genotoxic?." Journal of biomedicine & biotechnology vol. 2004,2 (2004): 93-98. doi: https://doi.org/10.1155/S1110724304307060
Arif JM, Al-Hazzani AA, Kunhi M, Al-Khodairy F. Novel Marine Compounds: Anticancer or Genotoxic?. J Biomed Biotechnol. 2004;2004(2):93-98. doi: 10.1155/S1110724304307060. PMID: 15240919; PMCID: PMC548801.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 16082422
Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005;27(5):331-72
Bayés, M., Rabasseda, X., & Prous, J. R. (2005). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 27(5), 331-72.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 27,5 (2005): 331-72.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72. PMID: 16082422.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 756 entries